[144] Beta Bionics, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Beta Bionics, Inc. (BBNX) reports a proposed sale of 4,413 shares of common stock through Merrill Lynch on 08/22/2025 with an aggregate market value of $75,082.65. The filing lists total shares outstanding of 43,470,125. The shares to be sold were acquired on 08/22/2025 as stock options from Beta Bionics and the stated payment method is cash. The filing also discloses two prior sales by Stephen Feider on 06/02/2025 (1,497 shares, $26,783.06) and 08/19/2025 (5,587 shares, $95,171.78).

Positive

• Disclosure compliance: Sale reported under Rule 144 with broker and transaction details
• Transparency of acquisition: Acquisition method listed as stock options from Beta Bionics and payment method as cash
• Historical sales provided: Prior sales on 06/02/2025 and 08/19/2025 are disclosed, improving traceability

Negative

• None.

Insights

Securities Analyst

TL;DR Routine insider sale under Rule 144; size is immaterial relative to outstanding shares, filed with broker details.

The notice documents an insider or related-person sale of 4,413 shares valued at $75,082.65 scheduled for 08/22/2025 through Merrill Lynch. Acquisition is shown as stock options granted by the issuer and paid in cash. Relative to 43,470,125 shares outstanding, this sale represents a de minimis percentage and is unlikely to be materially dilutive. Disclosure consistency with Rule 144 and prior sales by the same seller improves transparency for investors.

Corporate Governance Expert

TL;DR The filing reflects compliance with reporting obligations; recent insider sales are disclosed but not large enough to signal governance concerns.

The Form 144 includes required attestations and broker details, indicating process adherence. The seller represented no undisclosed material adverse information. Prior sales by the named individual are documented, supporting continuity of disclosure. No evidence in the filing of unusual transfer mechanisms or coordinated large disposals that would raise governance red flags.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 6002 El Tordo 2nd FL PO BOX 7297 Rancho Santa Fe CA 92067	4413	75082.65	43470125	08/22/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/22/2025	Stock Options	Beta Bionics			4413	08/22/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Stephen Feider 11 HUGHES Irvine CA 92618	Common	08/19/2025	5587	95171.78
Stephen Feider 11 HUGHES Irvine CA 92618	Common	06/02/2025	1497	26783.06

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Beta Bionics (BBNX) report?

The Form 144 reports a proposed sale of 4,413 common shares through Merrill Lynch on 08/22/2025 valued at $75,082.65.

How many shares outstanding does Beta Bionics report in the filing?

The filing lists 43,470,125 shares outstanding.

How were the shares being sold acquired according to the filing?

The shares were acquired on 08/22/2025 as stock options from Beta Bionics and the payment method is listed as cash.

Are there prior sales by the same seller disclosed?

Yes. The filing discloses prior sales by Stephen Feider: 1,497 shares on 06/02/2025 for $26,783.06 and 5,587 shares on 08/19/2025 for $95,171.78.

Through which broker will the sale be executed?

The sale is listed with Merrill Lynch (address provided in the filing).